Literature DB >> 2886764

Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone.

L S Freedman, M C Parkinson, W G Jones, R T Oliver, M J Peckham, G Read, E S Newlands, C J Williams.   

Abstract

259 patients with stage I non-seminomatous germ-cell testicular teratoma who were treated by orchidectomy alone and monitored at one often centres in the United Kingdom were followed for a median of 30 months. 62 of the 70 relapses occurred in the first 18 months after orchidectomy. The 2-year relapse-free rate was 74%, falling to 68% at 4 years. Histological sections from 233 of the orchidectomy specimens were reviewed centrally. Four features independently predicted relapses: invasion of testicular veins, invasion of testicular lymphatics, absence of yolk-sac elements, and presence of undifferentiated tumour. An index, based on the number of these features observed, identified a high-risk subgroup of 55 patients who had a 42% relapse-free rate at 2 years.

Entities:  

Mesh:

Year:  1987        PMID: 2886764     DOI: 10.1016/s0140-6736(87)90889-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  42 in total

1.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

Review 2.  Testicular cancer and related neoplasms.

Authors:  G M Mead
Journal:  BMJ       Date:  1992-05-30

Review 3.  Current Concepts in Management of Stage I NSGCT.

Authors:  Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2016-12-17

Review 4.  Testicular carcinoma.

Authors:  A O'Callaghan; G M Mead
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

Review 5.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 6.  Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Authors:  Andrew J Stephenson; Joel Sheinfeld
Journal:  Curr Treat Options Oncol       Date:  2005-09

7.  [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].

Authors:  M Hartmann; R Siener; S Krege; H Schmelz; K-P Dieckmann; A Heidenreich; P Kwasny; M Pechoel; J Lehmann; S Kliesch; K-U Köhrmann; R Fimmers; L Weissbach; V Loy; C Wittekind; P Albers
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

8.  Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.

Authors:  Soner Guney; Nese Guney; Nurettin Cem Sonmez; Erbil Ergenekon
Journal:  Med Oncol       Date:  2008-09-26       Impact factor: 3.064

9.  Management options for stage 1 nonseminomatous germ cell tumors of the testis.

Authors:  Stephen D W Beck
Journal:  Indian J Urol       Date:  2010 Jan-Mar

Review 10.  [Testis cancer: the UK as a model].

Authors:  S B Maddineni; N W Clarke
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.